- Data from novel proprietary neurotropic adeno-associated virus
(AAV) delivery capsid, STAC-BBB, demonstrated industry-leading
blood-brain barrier (BBB) penetration in non-human primates (NHPs)
following intravenous administration, with capsid-enabled delivery
of zinc finger payloads targeting prion disease and tauopathies
resulting in potent and widespread repression of target genes.
- Chronic neuropathic pain and prion disease preclinical programs
advance, with investigational new drug (IND) and clinical trial
authorization (CTA) submissions expected in the fourth quarters of
2024 and 2025, respectively.
- Announced U.S. Food and Drug Administration (FDA) alignment on
an abbreviated pathway to potential approval, and grant by European
Medicines Agency (EMA) of priority medicines (PRIME) eligibility
for isaralgagene civaparvovec in Fabry disease.
- Pfizer anticipates Biologics License Application (BLA) and
marketing authorization application (MAA) submissions for
Hemophilia A collaboration by early 2025 if the pivotal readout is
supportive.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines
company, today reported recent business highlights and fourth
quarter and full year 2023 financial results, including meaningful
data to support advancement of its neurology pipeline.
“In 2023, Sangamo announced the prioritization of its pipeline
programs that support our focus as a neurology-focused genomic
medicine company,” said Sandy Macrae, Chief Executive Officer of
Sangamo. “With the meaningful preclinical data announced today, we
believe our ability to combine potent zinc finger epigenetic
regulation payloads with exciting new industry-leading capsid
delivery technology could unlock significant potential for the
treatment of devastating neurological diseases, indications for
which delivery of treatments to the central nervous system has
historically proved challenging. In the near-term, we are also
seeking to create value by partnering our Fabry disease program,
for which we aligned with the FDA on a potentially abbreviated and
more cost-effective timeline and received EMA PRIME eligibility. We
look forward to advancing our pipeline into the clinic to develop
therapies designed to target neurological diseases with high unmet
medical needs.”
Recent Business Highlights
Prioritized Neurology Pipeline
Sangamo is developing epigenetic regulation therapies to treat
serious neurological diseases and novel proprietary AAV capsids
designed to deliver our therapies to the intended neurological
targets, including across the blood-brain barrier.
Novel AAV Capsid Delivery Technology – Data demonstrated
industry-leading BBB penetration and brain transduction in NHPs,
with capsid-enabled delivery of zinc finger payloads targeting
prion disease and tauopathies resulting in potent and widespread
repression of target genes.
- Novel STAC-BBB capsid demonstrated robust penetration of BBB
with 700-fold higher transgene expression in neurons compared to
the benchmark capsid AAV9 and outperformed all other known
published capsid variants evaluated in the study.
- STAC-BBB mediated robust expression of zinc finger cargo in
neurons, with potent and widespread repression of prion and tau
genes observed across key brain regions, demonstrating the
potential for modification of disease progression in prion disease
and various tauopathies.
- Visualization of gene expression in individual brain cells by
RNAscope revealed highly potent repression of tau in neurons
expressing the zinc finger cargo, across multiple brain
regions.
- Capsid biodistribution profile is optimal for the treatment of
neurological diseases with AAV-based treatments, highlighted by the
observed enrichment in the CNS and de-targeting from the liver,
dorsal root ganglia (DRG) and other peripheral organs.
- STAC-BBB was well tolerated in NHPs, with no notable treatment
related pathological findings in brain, spinal cord or peripheral
tissues.
- We believe that STAC-BBB is manufacturable at commercial scale
using standard cell culture and purification processes, is soluble
using known excipients, and can be characterized using available
analytics.
Chronic Neuropathic Pain – Preclinical data demonstrated
potent and specific repression of Nav1.7 expression without
impacting other sodium channels and that zinc finger repressors
(ZFRs) were well tolerated in NHPs; IND submission expected in
fourth quarter of 2024.
- IND-enabling toxicology studies are nearing completion.
- An IND submission is expected in the fourth quarter of
2024.
Prion Disease – Preclinical data demonstrated that
AAV-delivered ZFRs significantly reduced expression of the prion
protein in the brain, extended lifespan and limited formation of
toxic prion aggregates in mice; CTA expected in the fourth quarter
of 2025.
- CTA-enabling studies continue to advance.
- Prion-targeted zinc finger repressor, delivered via an
intravenous administration of the STAC-BBB novel capsid, resulted
in a dose-dependent repression of prion genes in NHPs.
- A CTA submission is expected in the fourth quarter of
2025.
Tauopathies – Preclinical data demonstrated that
AAV-delivered ZFRs significantly reduced expression of tau mRNA in
brain of NHPs; intend to resume development of this program,
leveraging STAC-BBB; IND submission expected as early as the fourth
quarter of 2025.
- Intend to resume development of our previously paused tau
program, leveraging the newly identified STAC-BBB capsid variant,
subject to additional funding.
- Tau clinical-lead zinc finger repressor, delivered via an
intravenous administration of the STAC-BBB novel capsid, resulted
in a dose-dependent repression of tau genes in NHPs. Visualization
of gene expression in individual brain cells by RNAscope revealed
highly potent repression of tau in neurons expressing the zinc
finger cargo across multiple brain regions.
- We expect the IND submission could occur as early as the fourth
quarter of 2025.
Other Programs
Fabry Disease – Dosed total of 32 patients in Phase 1/2
STAAR study, with updated clinical data presented at 20th Annual
WORLDSymposium showing sustained benefit and differentiated safety
profile; announced FDA alignment on abbreviated pathway to
potential approval; actively seeking collaboration partner to
advance asset toward potential registration and
commercialization.
- Dosed seven additional patients in the dose expansion phase of
the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, our
wholly owned gene therapy product for the treatment of Fabry
disease, for a total of 32 patients dosed to date.
- Presented updated clinical data at the 20th Annual
WORLDSymposium in San Diego, CA in February 2024, showing that
elevated levels of α-Gal A activity were sustained in all 24
patients evaluated as of the September 19, 2023 data cutoff date
and accompanied by the reduction and/or long-term stabilization of
lyso-Gb3 levels, with the largest reductions in plasma lyso-Gb3
seen in patients with the highest levels at baseline.
- All 13 patients who were withdrawn from Enzyme Replacement
Therapy (ERT) remain off ERT as of March 12, 2024.
- In the 13 patients followed for 12-months or more after
treatment, renal function remained stable, and significant
improvements in overall disease severity, quality of life, and
gastrointestinal symptoms compared to baseline were reported.
- Aligned with the FDA that data from a single, adequate, and
well-controlled study may form the primary basis of approval of a
BLA for isaralgagene civaparvovec, enabling a potentially
abbreviated and more cost-effective pathway to BLA submission than
originally anticipated. The study would enroll up to 25 patients,
both male and female, without the need for a control arm. A
head-to-head comparison with ERT is not part of the proposed study
design deemed acceptable by the FDA.
- Granted PRIME eligibility from the EMA for isaralgagene
civaparvovec, which aims to enhance support for the development of
medicines that target an unmet medical need and is intended to
optimize development plans and expedite review and approval
processes.
- Granted Innovative Licensing and Access Pathway (ILAP) for
isaralgagene civaparvovec from U.K. Medicines and Healthcare
products Regulatory Agency (MHRA) which aims to accelerate time to
market and facilitate access to medicines. Isaralgagene
civaparvovec has already received Orphan Medicinal Product
designation from the EMA as well as Orphan Drug, Fast Track and
Regenerative Medicine Advanced Therapy (RMAT) designations from the
FDA.
- Completed screening and enrollment in the Phase 1/2 STAAR study
and expect to complete dosing of remaining patients in the first
half of 2024.
- Deferring additional investments in planning for a potential
registrational trial until a collaboration partnership or financing
for this program is secured.
Hemophilia A (Pfizer) – Pivotal data read-out in Phase 3
AFFINE trial expected in mid-2024; BLA and MAA submissions
anticipated by early 2025 if pivotal readout is supportive.
- A pivotal readout is expected in mid-2024 in the Phase 3 AFFINE
trial of giroctocogene fitelparvovec, an investigational gene
therapy we are developing with Pfizer for patients with moderately
severe to severe hemophilia A.
- Pfizer anticipates BLA and MAA submissions by early 2025 if the
pivotal readout is supportive.
- Presented updated data with Pfizer from the Phase 1/2 ALTA
study of giroctocogene fitelparvovec in an oral presentation at the
65th American Society for Hematology Annual Meeting and Exposition
in December 2023.
- Eligible to earn from Pfizer up to $220.0 million in milestone
payments upon the achievement of certain regulatory and commercial
milestones for giroctocogene fitelparvovec and product sales
royalties of 14% - 20% if giroctocogene fitelparvovec is approved
and commercialized, subject to certain reductions.
CAR-Tregs – In alignment with previously announced
strategic transformation, announced winddown of the Company’s
French research and manufacturing operations and a corresponding
reduction in workforce; continuing to seek a potential
collaboration partner or external investment in the CAR-Treg cell
therapy programs.
- Announced a winddown of Sangamo’s French operations and a
corresponding reduction in workforce, including closure of
Sangamo’s cell therapy manufacturing facility and research labs in
Valbonne, France, which is expected to commence in April 2024 and
be complete by end of year. We expect this restructuring to result
in the elimination of all roles in France (approximately 93).
- Dosed two additional patients in the Phase 1/2 STEADFAST study
evaluating TX200, our wholly owned autologous CAR-Treg cell therapy
treating patients receiving an HLA-A2 mismatched kidney from a
living donor, including the first patient in the new fourth,
highest dose cohort.
- Expect to dose up to two additional patients in the fourth
highest-dose level cohort by the end of the second quarter of
2024.
- Plan to continue seeking a potential collaboration partner or
external investment in our autologous CAR-Treg cell therapy
programs.
Fourth Quarter and Full Year 2023 Financial Results
Consolidated net loss for the fourth quarter ended December 31,
2023 was $60.3 million, or $0.34 per share, compared to a net loss
of $52.0 million, or $0.32 per share, for the same period in 2022.
For the year ended December 31, 2023, consolidated net loss was
$257.8 million, or $1.48 per share, compared to consolidated net
loss of $192.3 million, or $1.25 per share, for the year ended
December 31, 2022.
Revenues
Revenues for the fourth quarter ended December 31, 2023 were
$2.0 million, compared to $27.2 million for the same period in
2022.
The decrease of $25.2 million in revenues was primarily
attributed to a decrease of $17.5 million in revenue relating to
our collaboration agreement with Kite, reflecting a reduction in
level of our research and development services, and a decrease of
$10.3 million in revenue relating to our collaboration agreement
with Novartis, due to the impact of termination of the
collaboration agreement. These decreases were partially offset by
an increase of $2.6 million in revenues from other licensing
agreements.
Revenues were $176.2 million in 2023, compared to $111.3 million
in 2022.
The increase of $64.9 million in revenues in 2023 compared to
2022, was primarily attributed to an increase of $106.4 million in
revenue relating to our collaboration agreement with Biogen,
primarily due to the impact of termination of the collaboration
agreement in June 2023, which resulted in an increase in the
measure of proportional cumulative performance on this
collaboration, an increase of $3.8 million in revenue relating to
our license agreement with Sigma-Aldrich Corporation, and an
increase of $3.6 million in revenues from other licensing
agreements. These increases were partially offset by a decrease of
$27.5 million in revenue relating to our collaboration agreement
with Novartis due to the termination of the collaboration agreement
in June 2023, a decrease of $18.1 million in revenue relating to
our collaboration agreement with Kite due to a reduction in the
estimated future level of our research and development services
related to this collaboration, and a decrease of $3.3 million in
revenue relating to our collaboration agreement with Sanofi due to
the termination of the collaboration agreement in June 2022.
GAAP and Non-GAAP Operating Expenses
Three Months Ended Year Ended December 31,
December 31, (In millions)
2023
2022
2023
2022
Research and development
$
50.7
$
66.2
$
234.0
$
249.9
General and administrative
13.1
16.4
61.2
62.7
Impairment of goodwill and indefinite-lived intangible assets
-
-
89.5
-
Impairment of long-lived assets
0.3
-
65.5
-
Total operating expenses
64.1
82.6
450.2
312.6
Impairment of goodwill and indefinite-lived intangible assets
-
-
(89.5
)
-
Impairment of long-lived assets
(0.3
)
-
(65.5
)
-
Depreciation and amortization
(1.8
)
(3.3
)
(15.1
)
(12.1
)
Stock-based compensation expense
(6.1
)
(8.3
)
(27.4
)
(31.7
)
Non-GAAP operating expenses
$
55.9
$
71.0
$
252.7
$
268.8
Total operating expenses on a GAAP basis for the fourth quarter
ended December 31, 2023 were $64.1 million compared to $82.6
million for the same period in 2022. Non-GAAP operating expenses,
which exclude impairment charges, depreciation and amortization,
and stock-based compensation expense, for the fourth quarter ended
December 31, 2023 were $55.9 million, compared to $71.0 million for
the same period in 2022.
The decrease in total operating expenses on a GAAP and non-GAAP
basis was primarily attributable to lower compensation and other
personnel costs mainly due to a reduction in the bonus expense and
lower headcount as a result of restructuring of operations and a
corresponding reduction in workforce announced during the year, and
a decrease in research and clinical expenses due to deferral and
reprioritization of certain programs. These decreases were
partially offset by restructuring charges related to the reductions
in workforce announced in April and November 2023, and the France
restructuring. The expense related to the France restructuring was
recorded in the fourth quarter of 2023 as the payouts are based an
ongoing post-employment benefit plan, and the payments were
probable and could be estimated as of December 31, 2023.
Total operating expenses on a GAAP basis in 2023 were $450.2
million compared to $312.6 million in 2022. Non-GAAP operating
expenses, which exclude impairment charges, depreciation and
amortization, and stock-based compensation expense, were $252.7
million in 2023 compared to $268.8 million in 2022.
Operating expenses on a GAAP basis included non-cash charges
relating to impairment of goodwill and indefinite-lived intangible
assets of $89.5 million, and impairment of long-lived assets of
$65.5 million, which were a result of continued decline in our
stock price and related market capitalization and termination of
our collaboration agreements with Biogen and Novartis. The decrease
in total operating expenses on a non-GAAP basis was primarily
attributable to a reduction in the bonus expense and lower
headcount as a result of restructurings of operations and
corresponding reductions in workforce announced during the year,
and a decrease in preclinical and clinical expenses due to the
termination of collaboration agreements with Biogen and Novartis
and deferral and reprioritization of certain programs. These
decreases were partially offset by restructuring charges related to
the reductions in workforce announced in April and November 2023,
and the France restructuring.
Cash, Cash Equivalents and Marketable Securities
Cash, cash equivalents and marketable securities as of December
31, 2023 were $81.0 million, compared to $307.5 million as of
December 31, 2022. During the year ended December 31, 2023, we
raised approximately $15.1 million in net proceeds under our
at-the-market offering program. We believe that our available cash,
cash equivalents and marketable securities as of December 31, 2023,
in combination with potential future cost reductions, will be
sufficient to fund our planned operations into the third quarter of
2024, excluding any additional capital raised. We are actively
pursuing opportunities to raise additional capital.
Financial Guidance for 2024
On a GAAP basis, we expect total operating expenses in the range
of approximately $145 million to $165 million in 2024, which
includes non-cash stock-based compensation expense and depreciation
and amortization, subject to additional funding.
We expect non-GAAP total operating expenses, excluding estimated
non-cash stock-based compensation expense of approximately $13
million, and depreciation and amortization of approximately $7
million, in the range of approximately $125 million to $145 million
in 2024, subject to additional funding.
Upcoming Events
Sangamo plans to participate in the following events:
Investor Conferences
- RBC Capital Markets Global Healthcare Conference, May 14-15,
2024
- Jefferies Global Healthcare Conference, June 5-6, 2024
- H.C. Wainwright 5th Annual Neuro Perspectives Virtual
Conference, June 27, 2024
Access links for available webcasts for these investor
conferences will be available on the Sangamo website in the
Investors and Media section under Events. Available materials will
be found on the Sangamo website after the event under
Presentations.
Conference Call
The Sangamo management team will hold a corporate call to
further discuss program advancements and financial updates on
Wednesday, March 13 at 4:30pm Eastern Time.
Participants should register for, and access, the call using
this link. While not required, it is recommended you join 10
minutes prior to the event start. Once registered, participants
will be given the option to either dial into the call with the
number and unique passcode provided or to use the dial-out option
to connect their phone instantly.
An updated corporate presentation is available in the Investors
and Media section under Presentations.
The link to access the live webcast can also be found on the
Sangamo website in the Investors and Media section under Events. A
replay will be available following the conference call, accessible
at the same link.
About Sangamo Therapeutics
Sangamo Therapeutics is a genomic medicine company dedicated to
translating ground-breaking science into medicines that transform
the lives of patients and families afflicted with serious
neurological diseases who do not have adequate or any treatment
options. Sangamo’s zinc finger epigenetic regulators are ideally
suited to potentially address devastating neurological disorders
and Sangamo’s capsid discovery platform is expanding delivery
beyond currently available intrathecal delivery capsids, including
in the central nervous system. Sangamo’s pipeline also includes
multiple partnered programs and programs with opportunities for
partnership and investment. To learn more, visit www.sangamo.com
and connect with us on LinkedIn and Twitter/X.
Forward-Looking Statements
This press release contains forward-looking statements regarding
our current expectations. These forward-looking statements include,
without limitation, statements relating to: the therapeutic and
commercial potential of Sangamo’s product candidates and its
engineered capsids, including the ability of STAC-BBB to unlock
potential for the treatment of various neurological diseases, the
anticipated plans and timelines of Sangamo and its collaborators
dosing patients in and conducting our ongoing and potential future
clinical trials and presenting clinical data from our clinical
trials, including expectations regarding the conclusion of dosing
in our Phase 1/2 STAAR study, plans for patient dosing in the
STEADFAST study, the anticipated advancement of Sangamo’s product
candidates to late-stage development, including plans to seek a
potential partner or additional financing to proceed with potential
future Phase 3 trials of isaralgagene civaparvovec and the design
and timing thereof, the timeline to present data from the Phase 3
AFFINE trial and to make BLA and MAA submissions for giroctocogene
fitelparvovec, the potential to earn milestone payments and receive
product sales royalties if giroctocogene fitelparvovec is approved
and commercialized, expectations regarding advancement of Sangamo’s
preclinical neurology programs, including announcement of data
from, and anticipated IND and CTA submissions related to, such
programs, plans to seek a partner for or investor in Sangamo’s
CAR-Treg program, expectations concerning Sangamo’s announced
winddown of our French research and manufacturing operations and a
corresponding reduction in workforce and the expected charges and
cost savings associated with such restructuring; future potential
cost reductions, Sangamo’s expected cash runway, Sangamo’s 2024
financial guidance related to GAAP and non-GAAP total operating
expenses, impairments and stock-based compensation, plans to
participate in industry and investor conferences, efforts to secure
additional funding, and other statements that are not historical
fact. These statements are not guarantees of future performance and
are subject to certain risks and uncertainties that are difficult
to predict. Factors that could cause actual results to differ
include, but are not limited to, risks and uncertainties related to
Sangamo’s lack of capital resources to fully develop, obtain
regulatory approval for and commercialize its product candidates,
including the ability to secure the funding or partnerships
required to advance its preclinical and clinical programs;
Sangamo’s ability to execute its restructurings as currently
contemplated; the actual charges associated with the restructurings
being higher than anticipated or changes to the assumptions on
which the estimated charges associated with the restructurings are
based; Sangamo’s ability to achieve projected cost savings in
connection with the restructurings and to further reduce operating
expenses; unintended consequences from the restructuring that
impact Sangamo’s business; Sangamo’s need for substantial
additional funding to execute our operating plan and to continue to
operate as a going concern, including the risk that Sangamo will be
unable to obtain the funding necessary to advance its preclinical
and clinical programs and to otherwise operate as a going concern,
in which case Sangamo may be required to cease operations entirely,
liquidate all or a portion of its assets and/or seek protection
under the U.S. Bankruptcy Code; the uncertain and costly research
and development process, including the risk that preclinical
results may not be indicative of results in any future clinical
trials; the effects of macroeconomic factors or financial
challenges, including as a result of the ongoing overseas conflict,
current or potential future bank failures, inflation and rising
interest rates, on the global business environment, healthcare
systems and business and operations of Sangamo and its
collaborators, including the initiation and operation of clinical
trials; the impacts of clinical trial delays, pauses and holds on
clinical trial timelines and commercialization of product
candidates; the uncertain timing and unpredictable nature of
clinical trial results, including the risk that therapeutic effects
in the Phase 3 AFFINE trial will not be durable in patients as well
as the risk that the therapeutic effects observed in the latest
preliminary clinical data from the Phase 1/2 STAAR study will not
be durable in patients and that final clinical trial data from the
study will not validate the safety and efficacy of isaralgagene
civaparvovec, and that the patients withdrawn from ERT will remain
off ERT; the unpredictable regulatory approval process for product
candidates across multiple regulatory authorities; reliance on
results of early clinical trials, which results are not necessarily
predictive of future clinical trial results, including the results
of any registrational trial of Sangamo’s product candidates; the
potential for technological developments that obviate technologies
used by Sangamo; Sangamo’s reliance on collaborators and its
potential inability to secure additional collaborations, and
Sangamo’s ability to achieve expected future operating results.
All forward-looking statements about our future plans and
expectations, including our financial guidance, are subject to our
ability to secure adequate additional funding. There can be no
assurance that Sangamo and its collaborators will be able to
develop commercially viable products. Actual results may differ
materially from those projected in these forward-looking statements
due to the risks and uncertainties described above and other risks
and uncertainties that exist in the operations and business
environments of Sangamo and its collaborators. These risks and
uncertainties are described more fully in Sangamo’s Securities and
Exchange Commission, or SEC, filings and reports, including in
Sangamo’s Annual Report on Form 10-K for the year ended December
31, 2023, and subsequent filings and reports that Sangamo makes
from time to time with the SEC. Forward-looking statements
contained in this announcement are made as of this date, and
Sangamo undertakes no duty to update such information except as
required under applicable law.
Non-GAAP Financial Measures
To supplement our financial results and guidance presented in
accordance with GAAP, we present non-GAAP operating expenses, which
excludes depreciation and amortization, stock-based compensation
expense and impairment of goodwill, indefinite-lived intangible
assets and long-lived assets from GAAP operating expenses. We
believe that this non-GAAP financial measure, when considered
together with our financial information prepared in accordance with
GAAP, can enhance investors’ and analysts’ ability to meaningfully
compare our results from period to period and to our
forward-looking guidance, and to identify operating trends in our
business. We have excluded depreciation and amortization, and
stock-based compensation expense because they are non-cash expenses
that may vary significantly from period to period as a result of
changes not directly or immediately related to the operational
performance for the periods presented, and we have excluded
impairment of goodwill, indefinite-lived intangible assets and
long-lived assets to facilitate a more meaningful evaluation of our
current operating performance and comparisons to our operating
performance in other periods. This non-GAAP financial measure is in
addition to, not a substitute for, or superior to, measures of
financial performance prepared in accordance with GAAP. We
encourage investors to carefully consider our results under GAAP,
as well as our supplemental non-GAAP financial information, to more
fully understand our business.
SELECTED CONSOLIDATED FINANCIAL DATA (unaudited; in
thousands, except per share data)
Statement of Operations Data: Three Months Ended
Year Ended December 31, December 31,
2023
2022
2023
2022
Revenues
$
2,042
$
27,230
$
176,232
$
111,299
Operating expenses: Research and development
50,706
66,179
234,057
249,898
General and administrative
13,099
16,443
61,167
62,682
Impairment of goodwill and indefinite-lived intangible assets
-
-
89,485
-
Impairment of long-lived assets
296
-
65,528
-
Total operating expenses
64,101
82,622
450,237
312,580
Loss from operations
(62,059
)
(55,392
)
(274,005
)
(201,281
)
Interest and other income, net
1,491
3,678
11,102
9,432
Loss before income taxes
(60,568
)
(51,714
)
(262,903
)
(191,849
)
Income tax (benefit) expense
(272
)
259
(5,072
)
429
Net loss
$
(60,296
)
$
(51,973
)
$
(257,831
)
$
(192,278
)
Basic and diluted net loss per share
$
(0.34
)
$
(0.32
)
$
(1.48
)
$
(1.25
)
Shares used in computing basic and diluted net loss per share
177,619
164,717
174,444
154,345
Selected Balance Sheet Data: December 31, 2023
December 31, 2022 Cash, cash equivalents, and
marketable securities
$
81,002
$
307,477
Total assets
$
165,320
$
562,509
Total stockholders' equity
$
82,887
$
294,958
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240313945090/en/
Investor Relations & Media
Inquiries Louise Wilkie ir@sangamo.com media@sangamo.com
Sangamo Therapeutics (NASDAQ:SGMO)
過去 株価チャート
から 4 2024 まで 5 2024
Sangamo Therapeutics (NASDAQ:SGMO)
過去 株価チャート
から 5 2023 まで 5 2024